Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

2(33.3%)

N/A

2(33.3%)

Phase 3

2(33.3%)

6Total

Phase 2(2)

N/A(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06437080Not ApplicableCompleted

Hypoferritinemia Without Anemia Among Reproductive Age Females

Role: collaborator

NCT05080530Not ApplicableUnknown

Vitamin D and Painful Diabetic Neuropathy

Role: collaborator

NCT05417880Phase 3Unknown

Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus

Role: lead

NCT05104970Phase 2Unknown

Comparative Pharmacokinetics of Two Different Oral Delivery Systems of Cholecalciferol

Role: lead

NCT05088928Phase 2Unknown

Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care

Role: lead

NCT05104918Phase 3Unknown

Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities

Role: lead

All 6 trials loaded